Investors & News
Corporate ProfileImago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of blood cancers. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. The company is advancing the clinical development of its first internally discovered LSD1 inhibitor, bomedemstat, for the treatment of myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating bomedemstat in three Phase 2 clinical studies for essential thrombocythemia (ET), myelofibrosis (MF) and polycythemia vera (PV). Learn more about our clinical pipeline here. The company is based in South San Francisco, California.
Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
Data Provided by Refinitiv. Minimum 15 minutes delayed.